JP2013517300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517300A5 JP2013517300A5 JP2012549209A JP2012549209A JP2013517300A5 JP 2013517300 A5 JP2013517300 A5 JP 2013517300A5 JP 2012549209 A JP2012549209 A JP 2012549209A JP 2012549209 A JP2012549209 A JP 2012549209A JP 2013517300 A5 JP2013517300 A5 JP 2013517300A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- pharmaceutical composition
- alkyl
- formula
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 150000002431 hydrogen Chemical class 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 31
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- -1 phenoxy, benzyloxy Chemical group 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 19
- 230000007830 nerve conduction Effects 0.000 claims description 12
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 11
- 235000010290 biphenyl Nutrition 0.000 claims description 10
- 239000004305 biphenyl Substances 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 150000001735 carboxylic acids Chemical class 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- DLOJNSZTAIAJRU-UHFFFAOYSA-N n-benzyl-2-phenylaniline Chemical group C=1C=CC=CC=1CNC1=CC=CC=C1C1=CC=CC=C1 DLOJNSZTAIAJRU-UHFFFAOYSA-N 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims description 9
- 235000021317 phosphate Nutrition 0.000 claims description 9
- 125000005541 phosphonamide group Chemical group 0.000 claims description 9
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- 150000003456 sulfonamides Chemical class 0.000 claims description 9
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000002981 neuropathic effect Effects 0.000 claims description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 3
- GHBCIXGRCZIPNQ-UHFFFAOYSA-N 2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound COC1=CC=C2CN(C(=O)C(C=3C=CC=CC=3)C=3C=CC=CC=3)C(C(O)=O)CC2=C1OCC1=CC=CC=C1 GHBCIXGRCZIPNQ-UHFFFAOYSA-N 0.000 claims description 2
- 206010021089 Hyporeflexia Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 206010040021 Sensory abnormalities Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 230000011514 reflex Effects 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 238000000034 method Methods 0.000 description 30
- 0 Cc1c(C)nc(*)[n]1* Chemical compound Cc1c(C)nc(*)[n]1* 0.000 description 8
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 230000006735 deficit Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29637510P | 2010-01-19 | 2010-01-19 | |
| US61/296,375 | 2010-01-19 | ||
| PCT/AU2011/000051 WO2011088504A1 (en) | 2010-01-19 | 2011-01-19 | Methods and compositions for improved nerve conduction velocity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016073914A Division JP2016155846A (ja) | 2010-01-19 | 2016-04-01 | 神経伝導速度改善のための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013517300A JP2013517300A (ja) | 2013-05-16 |
| JP2013517300A5 true JP2013517300A5 (https=) | 2014-02-27 |
| JP6232184B2 JP6232184B2 (ja) | 2017-11-15 |
Family
ID=44306296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549209A Expired - Fee Related JP6232184B2 (ja) | 2010-01-19 | 2011-01-19 | 神経伝導速度改善のための方法および組成物 |
| JP2016073914A Pending JP2016155846A (ja) | 2010-01-19 | 2016-04-01 | 神経伝導速度改善のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016073914A Pending JP2016155846A (ja) | 2010-01-19 | 2016-04-01 | 神経伝導速度改善のための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9095587B2 (https=) |
| EP (1) | EP2525795B1 (https=) |
| JP (2) | JP6232184B2 (https=) |
| CN (2) | CN107744519A (https=) |
| AU (1) | AU2011207104C1 (https=) |
| CA (1) | CA2787173C (https=) |
| ES (1) | ES2560327T3 (https=) |
| NZ (1) | NZ601383A (https=) |
| WO (1) | WO2011088504A1 (https=) |
| ZA (1) | ZA201205375B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011281381B2 (en) * | 2010-07-21 | 2015-07-16 | Novartis Ag | Salt and solvates of a tetrahydroisoquinoline derivative |
| WO2012135365A2 (en) * | 2011-03-29 | 2012-10-04 | Biolyst, Llc | Systems and methods for use in treating sensory impairment |
| ES2802251T3 (es) | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| PT2807171T (pt) * | 2012-01-25 | 2020-11-03 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
| ES2798289T3 (es) | 2012-01-25 | 2020-12-10 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| ES2883155T3 (es) * | 2013-07-08 | 2021-12-07 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| JP6667551B2 (ja) | 2015-01-13 | 2020-03-18 | ノバルティス アーゲー | アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体 |
| US10308628B2 (en) | 2015-03-12 | 2019-06-04 | Novartis Ag | Heterocyclic compounds and methods for their use |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| PT3620454T (pt) * | 2017-06-09 | 2021-09-10 | Shandong Danhong Pharmaceutical Co Ltd | Derivado de ácido carboxílico como antagonista do recetor at2r |
| KR102619333B1 (ko) * | 2018-11-02 | 2023-12-28 | 산동 단홍 파머수티컬 컴퍼니., 리미티드. | 안지오텐신ii 수용체2 길항제의 염 형태, 결정형 및 그 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091390A (en) * | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| AU675935B2 (en) | 1992-04-13 | 1997-02-27 | Astrazeneca Ab | Angiotensin II antagonists against disorders associated withimpaired neuronal conduction velocity, especially diabetic neuropathy |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| GB2337701A (en) * | 1998-05-26 | 1999-12-01 | United Medical And Dental Schools Of Guys St Thomas Hospitals | Treatment of ischemia with an angiotensin II antagonist |
| WO2006066361A1 (en) * | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| CA2866540A1 (en) * | 2006-03-20 | 2007-09-27 | Spinifex Pharmaceuticals Pty Ltd. | Method of treatment or prophylaxis of inflammatory pain |
| US7828840B2 (en) | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
-
2011
- 2011-01-19 NZ NZ60138311A patent/NZ601383A/en not_active IP Right Cessation
- 2011-01-19 CA CA2787173A patent/CA2787173C/en not_active Expired - Fee Related
- 2011-01-19 AU AU2011207104A patent/AU2011207104C1/en not_active Ceased
- 2011-01-19 ES ES11734246.9T patent/ES2560327T3/es active Active
- 2011-01-19 JP JP2012549209A patent/JP6232184B2/ja not_active Expired - Fee Related
- 2011-01-19 EP EP11734246.9A patent/EP2525795B1/en active Active
- 2011-01-19 WO PCT/AU2011/000051 patent/WO2011088504A1/en not_active Ceased
- 2011-01-19 CN CN201711036658.8A patent/CN107744519A/zh active Pending
- 2011-01-19 US US13/522,228 patent/US9095587B2/en not_active Expired - Fee Related
- 2011-01-19 CN CN2011800145791A patent/CN102821765A/zh active Pending
-
2012
- 2012-07-18 ZA ZA2012/05375A patent/ZA201205375B/en unknown
-
2016
- 2016-04-01 JP JP2016073914A patent/JP2016155846A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517300A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| JP2007523155A5 (https=) | ||
| JP2017528503A5 (https=) | ||
| JP2013523733A5 (https=) | ||
| JP2012255002A5 (https=) | ||
| JP2015520151A5 (https=) | ||
| JP2008509187A5 (https=) | ||
| JP2015512931A5 (https=) | ||
| CN103781766A (zh) | 用作鞘氨醇-1磷酸酯受体调节剂的取代的双环甲胺衍生物 | |
| JP2010522710A5 (https=) | ||
| JP2015502974A5 (https=) | ||
| JP2011524850A5 (https=) | ||
| JP2005535592A5 (https=) | ||
| JP2008519840A5 (https=) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| JP2009511568A5 (https=) | ||
| JP2015516429A5 (https=) | ||
| JP2015051983A5 (https=) | ||
| JP2017511377A5 (https=) | ||
| JP2019532926A5 (https=) | ||
| JP2017522300A5 (https=) | ||
| WO2010020585A1 (en) | Serotonin reuptake inhibitors for the treatment of rett syndrome | |
| JP2018537507A5 (https=) | ||
| JP2009511450A5 (https=) |